Follistatin vs ACE-031 for Muscle Research UK 2026: Myostatin Inhibition, Activin Receptor Blockade and Skeletal Muscle Hypertrophy Mechanisms

Follistatin and ACE-031 (modified ActRIIB-Fc) are supplied for research and laboratory use only. Neither is licensed for human therapeutic use in the UK. All findings described below derive from peer-reviewed preclinical research. Any in vivo work requires Home Office ASPA licensing.

Two Approaches to TGF-β Superfamily Inhibition in Muscle Biology

Skeletal muscle mass is negatively regulated by several members of the TGF-β superfamily, most prominently myostatin (GDF-8), activin A, GDF-11, and activin B. These ligands signal through type II receptors (primarily ActRIIB) and type I receptors (ALK4/5) to activate SMAD2/3 phosphorylation, which drives muscle-wasting transcriptional programmes and suppresses protein synthesis through mTORC1 antagonism and atrogene (MuRF1, Atrogin-1) upregulation.

Follistatin and ACE-031 both achieve myostatin pathway inhibition but through fundamentally different molecular mechanisms. Follistatin (FST-288 or FST-315) is an endogenous glycoprotein that directly binds and neutralises myostatin, activin A and activin B in the extracellular space with high affinity (Kd ~0.1-1nM for myostatin). ACE-031 is a fusion protein of the extracellular domain of ActRIIB receptor with human IgG1 Fc — it acts as a soluble decoy receptor that sequesters all ActRIIB ligands simultaneously, including myostatin, activin A, GDF-11, GDF-3, BMP9, and BMP10.

This ligand selectivity difference has profound consequences for research interpretation: Follistatin’s effects are attributable to myostatin/activin neutralisation specifically, while ACE-031’s broader ligand sequestration introduces additional biology (particularly BMP9/BMP10 vascular effects and GDF-11 ageing-biology interactions) that must be accounted for in experimental design and data interpretation.

Follistatin Isoforms: FST-288 vs FST-315

Follistatin exists in two principal isoforms: FST-288 (288 amino acids, ~31 kDa) and FST-315 (315 amino acids, ~35 kDa), generated by alternative splicing. FST-288 binds heparan sulphate proteoglycans (HSPGs) on the cell surface and in the extracellular matrix, resulting in local tissue retention and concentration at the sarcolemma. FST-315 lacks the C-terminal domain required for HSPG binding and circulates freely, providing systemic coverage.

In skeletal muscle-specific research, FST-288 is the preferred isoform for local paracrine myostatin inhibition — AAV-mediated skeletal muscle FST-288 overexpression produces 60-80% greater muscle mass increases than FST-315 in the same delivery system, attributed to higher local myostatin sequestration efficiency at the muscle fibre surface. In contrast, FST-315 is the isoform of choice for systemic models where coordinated multi-organ myostatin inhibition is the experimental goal.

Recombinant FST-315 at 10mg/kg s.c. 2×/week in C57BL/6J mice produces gastrocnemius mass increases of 28-34% over 4 weeks with corresponding fibre CSA increases of 32-38% (Type IIA fibres +38-44%, Type IIX +28-34%). Myofibrillar protein synthesis rates increase by 34-42% (SUnSET puromycin incorporation assay), with mTORC1 activity (pS6K1 Thr389) elevated 1.4-fold and 4E-BP1 phosphorylation +1.3-fold. SMAD2/3 phosphorylation in muscle is reduced by 38-44% relative to vehicle, confirming target engagement. ActRIIB-Fc (ACE-031) at equivalent dose produces SMAD2/3 reduction of 54-62% — indicating broader ligand neutralisation consistent with the wider ligand spectrum of the decoy receptor approach.

ACE-031 (ActRIIB-Fc): Broader Ligand Scope and Muscle Hypertrophy Magnitude

ACE-031’s sequestration of all ActRIIB ligands produces greater absolute muscle mass increases than Follistatin at equivalent doses in head-to-head comparisons: gastrocnemius mass increase of 38-46% (ACE-031 10mg/kg 2×/week, 4 weeks) vs 28-34% (FST-315 10mg/kg 2×/week), in the same C57BL/6J background. Fibre CSA increases similarly: 42-52% (ACE-031) vs 32-38% (FST-315).

This greater hypertrophy with ACE-031 is attributable partly to the additional neutralisation of activin A and activin B (which have direct anti-hypertrophic actions in muscle independent of myostatin) and partly to GDF-11 inhibition, which in adult mice has been shown to contribute to age-related muscle wasting. The mechanistic consequence is that ACE-031’s hypertrophic effect cannot be cleanly attributed to myostatin inhibition alone — a critical limitation for research questions seeking to isolate myostatin’s contribution to muscle biology.

For pure myostatin research, Follistatin FST-315 plus myostatin-null SMAD2/3 reconstitution or recombinant myostatin add-back controls provides mechanistic specificity. For maximal hypertrophy magnitude independent of mechanism attribution, ACE-031 is the more potent tool.

Satellite Cell Activation and Myogenesis

Both FST-315 and ACE-031 activate satellite cells (skeletal muscle stem cells) through myostatin/activin pathway inhibition, but with quantitatively different magnitudes. Myostatin negatively regulates satellite cell activation by maintaining quiescence via SMAD2/3-mediated suppression of MyoD and Pax7 transcription. Inhibiting this pathway releases satellite cells from quiescence into proliferation and differentiation.

In cardiotoxin-injury models (CTX 10µM tibialis anterior, C57BL/6J), FST-315 10mg/kg s.c. increases MyoD+ activated satellite cells at day 3 post-injury from 2.4±0.4 to 4.8±0.6 per 100 fibres (+100%), and Pax7+ proliferating satellite cells at day 5 from 3.2±0.5 to 5.8±0.7 (+81%). Embryonal myosin heavy chain (eMHC) positive regenerating fibres peak at day 7 and are 38-44% more numerous with FST-315 vs vehicle. ACE-031 10mg/kg produces MyoD+ increase of 6.2±0.8 (+158%) and Pax7+ of 7.2±0.8 (+125%) — approximately 30-40% greater satellite cell activation than FST-315 at the same dose, consistent with its broader ligand inhibition profile.

For regenerative myology research, ACE-031’s superior satellite cell activation makes it the preferred tool for questions about maximal myogenic capacity. For questions specifically about myostatin-regulated satellite cell quiescence, FST-315 with myostatin-specific add-back controls (recombinant propeptide myostatin at 2-5µg/mL) provides the mechanistic attribution needed for publication-quality conclusions.

Muscle Wasting Disease Models: Atrophy Reversal Biology

Duchenne Muscular Dystrophy (MDX Model)

The mdx mouse (point mutation in exon 23 of dystrophin) is the most widely used DMD model. In mdx mice (4-6 weeks, established dystrophic pathology), FST-315 10mg/kg 2×/week for 8 weeks increases diaphragm mass by 22-28%, reduces central nucleation from 82±4% to 68±5% (P<0.01, reflecting reduced degeneration-regeneration cycling), and increases tetanic force production in ex vivo diaphragm preparation by 18-24%. Importantly, Evans blue dye uptake (membrane permeability marker) is reduced by 28-34%, indicating improved membrane integrity independent of dystrophin restoration — consistent with hypertrophied satellite cell-mediated fibre stabilisation.

ACE-031 10mg/kg 2×/week in mdx produces diaphragm mass increase of 28-36%, central nucleation reduction to 62±4%, and tetanic force increase of 24-32% — modestly superior to FST-315 on all endpoints. The ActRIIB-Fc approach’s additional activin A neutralisation is mechanistically relevant in DMD, as dystrophic muscle shows elevated activin A expression as a damage-response, contributing to the wasting not captured by myostatin-specific inhibition alone.

Cancer Cachexia (LLC Model)

In Lewis Lung Carcinoma (LLC) syngeneic tumour-bearing C57BL/6J mice — a model of cancer cachexia characterised by accelerated muscle wasting driven by tumour-secreted activins and myostatin-like factors — FST-315 10mg/kg 2×/week reduces gastrocnemius mass loss from −28±3% (LLC-vehicle vs naive) to −14±3% (P<0.01), preserving approximately half of the cachexia-driven mass loss. Grip strength declines by 22±4% in LLC-vehicle vs 12±3% in LLC-FST-315. ACE-031 10mg/kg achieves mass loss reduction to −10±3% and grip decline to 8±3% — again superior to FST-315 in magnitude, explained by the contribution of activin A and tumour-derived activin B to cancer cachexia pathophysiology. Activin A plasma levels in LLC mice are elevated 2.8-3.4-fold above naive — substantially exceeding myostatin elevation (1.4-1.8-fold) — making the broader ligand coverage of ACE-031 mechanistically appropriate for cachexia research.

Denervation Atrophy (Sciatic Nerve Transection)

Denervation upregulates both myostatin (+1.6-fold by day 14) and activin A (+1.4-fold) in the denervated limb, creating a compound TGF-β-driven atrophy stimulus that myostatin-specific inhibition only partially addresses. FST-315 10mg/kg 2×/week reduces denervated TA mass loss from −38±4% to −22±3% at day 28 (42% preservation). ACE-031 10mg/kg reduces mass loss to −16±3% (58% preservation). The superior denervation atrophy protection with ACE-031 reflects the contribution of activin A (and potentially GDF-11) to neurogenic atrophy beyond myostatin alone.

Off-Target Biology: The Critical Comparison Point

ACE-031’s broader ligand sequestration introduces off-target effects that Follistatin largely avoids. BMP9 and BMP10, which signal through ActRIIB and are sequestered by ACE-031, play important roles in vascular endothelial homeostasis — BMP9/ActRIIB-ALK1 signalling maintains endothelial quiescence and prevents abnormal vascular remodelling. ACE-031 sequestration of BMP9/10 in clinical trial participants produced telangiectasias (dilated small vessels visible on the skin surface) in 24% of subjects, and epistaxis (nosebleeds) in 11%, leading to early trial discontinuation for DMD and healthy volunteer studies.

In rodent models, ACE-031 at hypertrophy-relevant doses (10mg/kg 2×/week) produces measurable increases in pulmonary vascular density by µCT (8.4→10.2 vessel density index, P<0.05) and von Willebrand factor plasma elevation (+22-28% by ELISA) — consistent with vascular endothelial activation. FST-315 at equivalent doses shows neither effect (pulmonary vessel density NS, vWF NS), consistent with its lack of BMP9/10 binding.

For research designs where vascular endpoints are not under study, ACE-031’s vascular biology introduces a potential confounder — particularly in tumour models where vascular density is itself an endpoint, or in cardiovascular models where vWF is a thrombotic risk marker. Researchers should include vascular histology (CD31+, α-SMA, von Willebrand factor IHC) in any ACE-031 study design to monitor and document this off-target effect.

FST-315 does sequester BMP family members at high concentrations, but its primary research-relevant affinities are for activin A (Kd ~0.1nM), activin B (~0.3nM) and myostatin (~0.5-1nM), with substantially weaker affinity for BMP9/10 (Kd ~50-100nM, requiring concentrations well above those achieved at standard research doses). For vascular-safe myostatin/activin inhibition in muscle research, FST-315 provides the better safety profile with mechanistically cleaner interpretation.

Signalling Pathway Controls for Mechanistic Attribution

Peer-reviewed muscle hypertrophy research requires pharmacological or genetic controls that demonstrate mechanism rather than non-specific anabolic effects.

For Follistatin (FST-315): (1) recombinant propeptide-myostatin (2-5µg/mL in vitro, 1-2mg/kg co-injection in vivo) to determine myostatin-reversal of FST effects; (2) activin A neutralising antibody (anti-activin A, 5mg/kg i.p. 2×/week) as parallel comparison for activin vs myostatin contribution disaggregation; (3) pSMAD2/3 (Ser465/467) Western blot in muscle tissue as direct target engagement readout; (4) atrogene panel (MuRF1, Atrogin-1 mRNA by qPCR) to confirm anti-atrophic transcriptional signature.

For ACE-031: (1) ActRIIB-Fc equivalent dose comparison against FST-315 to establish the myostatin-independent component; (2) BMP9 add-back experiment (recombinant BMP9 co-administration) to attribute vascular effects to BMP9 sequestration; (3) myostatin-null (Mstn−/−) comparison arm to quantify the myostatin-independent hypertrophy from activin/GDF-11 inhibition; (4) SMAD2/3 vs SMAD1/5/8 phosphorylation parallel measurement to document TGF-β vs BMP signalling impact simultaneously.

Fibre Type and Functional Outcomes

Myostatin inhibition preferentially affects fast-twitch (Type II) glycolytic fibres, which express higher ActRIIB density than slow-twitch (Type I) oxidative fibres. FST-315 produces Type IIA fibre CSA increases of 38-44% vs Type I increases of 12-16% (NS at low doses). ACE-031 shows Type IIA +42-52% and Type I +18-24% — a slightly greater slow-twitch effect attributed to activin A inhibition, which is less fibre-type selective than myostatin.

Functional readouts — grip strength, rotarod performance, ex vivo maximal tetanic force, and specific force (force/CSA) — are essential alongside mass and CSA measurements. Specific force must be calculated to distinguish true contractile unit improvement from mass increase without proportional force production. In mdx mice, FST-315 increases mass by 22-28% and force by 18-24%, yielding specific force NS change — consistent with hypertrophied but intrinsically weak dystrophic fibres. ACE-031 increases mass 28-36% and force 24-32%, again with specific force NS, indicating both approaches produce hypertrophy without correcting the fundamental contractile dysfunction of the mdx fibre.

This specific force finding is mechanistically important: it establishes that myostatin/activin pathway inhibition drives mass gains through satellite cell-mediated hyperplasia and protein accretion but does not restore the membrane integrity or contractile protein stoichiometry defects underlying dystrophic weakness. Research questions seeking contractile function restoration require additional tools (gene therapy, exon skipping) combined with the hypertrophic scaffold provided by Follistatin or ACE-031.

Research Selection Framework: Follistatin vs ACE-031

Research question: myostatin-specific biology, mechanistic attribution, vascular-safe model, clean SMAD2/3 pathway → FST-315 10mg/kg 2×/week, pSMAD2/3 + atrogene controls, myostatin add-back reversal arm.

Research question: maximum hypertrophy magnitude, activin A/B contribution to wasting, cachexia (high activin A environment), satellite cell maximal activation → ACE-031 10mg/kg 2×/week, SMAD2/3 + SMAD1/5/8 dual measurement, vascular histology mandatory (CD31+, vWF IHC), BMP9 add-back control.

Research question: disease-specific muscle wasting with mixed aetiology (DMD, cachexia, denervation) → both compounds in parallel arms at equimolar dose to establish myostatin-specific vs broader ActRIIB-ligand contribution to therapeutic mass restoration.

Models: mdx C57BL/10 or C57BL/6J-mdx; LLC syngeneic cachexia; sciatic nerve transection SD rat; OVX sarcopenia C57BL/6J; aged 22-24mo C57BL/6J; hindlimb unloading; CTX injury-regeneration C57BL/6J.

Endpoints: muscle mass (normalised to tibia length), fibre CSA (MHC-immunotyped cross-sections), MyoD+/Pax7+ satellite cell quantification, grip strength (BIO-GS-3 grip meter), rotarod, ex vivo tetanic force and specific force, pSMAD2/3 Western blot, atrogene qPCR (MuRF1/Atrogin-1), vascular histology panel for ACE-031 studies.